Various clinical trials are currently investigating therapeutic strategies aimed at inhibiting MDM2, including small-molecule inhibitors, antisense oligonucleotides, and peptides designed to disrupt the MDM2–p53 interaction, highlighting its potential as a viable approach for soft tissue sarcoma treatment [99]. The gene discussed is TP53; the disease is soft tissue sarcoma.